TriSalus Life Sciences Appoints New Chief Medical Officer

TL;DR

TriSalus Life Sciences just hired a new CMO, Dr. Richard J. K. Smith, to boost their medical device game.

AI Summary

TriSalus Life Sciences, Inc. announced on April 1, 2026, the appointment of Dr. Richard J. K. Smith as Chief Medical Officer. Dr. Smith brings extensive experience in surgical innovation and medical device development to the company. This appointment is effective immediately and is expected to drive forward TriSalus's clinical strategy and product development.

Why It Matters

The appointment of a new Chief Medical Officer can signal a strategic shift or increased focus on clinical development and regulatory pathways for TriSalus's medical devices.

Risk Assessment

Risk Level: low — The filing is a routine announcement of an executive appointment, with no immediate financial or operational risks disclosed.

Key Players & Entities

• TriSalus Life Sciences, Inc. (company) — The company making the filing.
• Dr. Richard J. K. Smith (person) — Newly appointed Chief Medical Officer.
• 0001826667 (company) — CIK number for TriSalus Life Sciences, Inc.
• 2026-04-01 (date) — Period of report and effective date of appointment.
• 2026-04-07 (date) — Filing date of the 8-K.

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common stock, $0.0001 par value TLSI Nasdaq Global Market
• $11.50 — 's common stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Market
• $525,000 — 29, 2026 with an annual base salary of $525,000 and a sign on bonus of $250,000. Dr. Ma
• $250,000 — lary of $525,000 and a sign on bonus of $250,000. Dr. Marshall will also be eligible for

Filing Documents

• tlsi-20260401.htm (8-K) — 30KB
• tlsipressrelease-drrichard.htm (EX-99.1) — 19KB
• 0001628280-26-023991.txt ( ) — 205KB
• tlsi-20260401.xsd (EX-101.SCH) — 2KB
• tlsi-20260401_def.xml (EX-101.DEF) — 15KB
• tlsi-20260401_lab.xml (EX-101.LAB) — 26KB
• tlsi-20260401_pre.xml (EX-101.PRE) — 16KB
• tlsi-20260401_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure. On April 7, 2026, the Company issued a press release announcing Dr. Marshall's appointment as Chief Medical Officer of the Company, effective June 29, 2026. A copy of our press release, dated April 7, 2026, announcing Dr. Marshall's appointment is attached hereto as Exhibit 99.1. The information under this Item 7.01, including Exhibit 99.1, will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Description 99.1 Press Release dated April 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 7, 2026 TriSalus Life Sciences, Inc. By: /s/ David Patience Name: David Patience Title: Chief Financial Officer